BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29950327)

  • 1. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.
    Kronbichler A; Kerschbaum J; Gopaluni S; Tieu J; Alberici F; Jones RB; Smith RM; Jayne DRW
    Ann Rheum Dis; 2018 Oct; 77(10):1440-1447. PubMed ID: 29950327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for serious infections in ANCA-associated vasculitis.
    Odler B; Riedl R; Gauckler P; Shin JI; Leierer J; Merkel PA; St Clair W; Fervenza F; Geetha D; Monach P; Jayne D; Smith RM; Rosenkranz A; Specks U; Stone JH; Kronbichler A;
    Ann Rheum Dis; 2023 May; 82(5):681-687. PubMed ID: 36702528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis.
    Cohen Tervaert JW
    Curr Opin Rheumatol; 2018 Jul; 30(4):388-394. PubMed ID: 29621029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab resistance at 3months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: A French multicentre retrospective study in 116 patients.
    Machet T; Quémeneur T; Ledoult E; Mesbah R; Lebas C; Hachulla E; Pokeerbux MR
    Joint Bone Spine; 2023 Sep; 90(5):105591. PubMed ID: 37230162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
    Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
    Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimethoprim-sulfamethoxazole prophylaxis during treatment of granulomatosis with polyangiitis with rituximab in the United States of America: a retrospective cohort study.
    Mendel A; Behlouli H; de Moura CS; Vinet É; Curtis JR; Bernatsky S
    Arthritis Res Ther; 2023 Jul; 25(1):133. PubMed ID: 37516897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide.
    Nettleton E; Sattui SE; Wallace Z; Putman M
    Arthritis Care Res (Hoboken); 2024 Feb; 76(2):288-294. PubMed ID: 37643919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis.
    Monti S; Delvino P; Riboli M; Rebuffi C; Xoxi B; De Silvestri A; Montecucco C
    Rheumatology (Oxford); 2021 Aug; 60(8):3553-3564. PubMed ID: 33752235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.
    Arnold J; Vital EM; Dass S; Aslam A; Rawstron AC; Savic S; Emery P; Md Yusof MY
    Front Immunol; 2021; 12():803175. PubMed ID: 35095887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Kronbichler A; Leierer J; Shin JI; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CGM; St Clair EW; Brunetta P; Fervenza FC; Geetha D; Keogh KA; Monach PA; Ytterberg SR; Mayer G; Specks U; Stone JH;
    Arthritis Rheumatol; 2019 Nov; 71(11):1888-1893. PubMed ID: 31216123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Li ZY; Chen M; Zhao MH
    Kidney Dis (Basel); 2021 Jan; 7(1):50-56. PubMed ID: 33614733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Should patients with ANCA-associated vasculitis undergoing maintenance therapy with rituximab receive cotrimoxazole prophylaxis?].
    Mahrhofer H
    Z Rheumatol; 2024 Mar; 83(2):122-124. PubMed ID: 38272971
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to: 'Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis' by Wallace
    Kronbichler A; Kerschbaum J
    Ann Rheum Dis; 2020 Apr; 79(4):e41. PubMed ID: 30700424
    [No Abstract]   [Full Text] [Related]  

  • 17. No evident association of nasal carriage of Staphylococcus aureus or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses.
    Tan BK; Crabol Y; Tasse J; Laurent F; Nekkab N; Vinter C; Puéchal X; Guillevin L
    Rheumatology (Oxford); 2020 Jan; 59(1):77-83. PubMed ID: 31834404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis.
    Thery-Casari C; Euvrard R; Mainbourg S; Durupt S; Reynaud Q; Durieu I; Belot A; Lobbes H; Cabrera N; Lega JC
    Autoimmun Rev; 2020 May; 19(5):102505. PubMed ID: 32173512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening.
    Xu T; Chen Z; Jiang M; Ma H; Jin K; Wang Z; Wang C; Xu J; Zhang W
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36270741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.